Genocea’s mission is to harness human biology to develop cancer immunotherapies for any patient by unlocking the targets that matter most. Our proprietary ATLAS™ technology is a clinically-validated platform that uniquely profiles the T cell repertoire and tumors, by selecting the therapeutically relevant antigens that drive powerful anti-tumor immune responses. ATLAS™ is the only platform able to identify Inhibigens™, or inhibitory antigens that dampen the immune response.

ATLAS™ drives Genocea’s emerging immunotherapy pipeline of best-in-class clinical stage programs. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Feb 11, 2021
Genocea Provides Fourth Quarter 2020 Corporate Update
GEN-011 and GEN-009 clinical trials continue to advance ATLAS TM stimulatory antigen and inhibitory antigen (Inhibigen TM ) identification profiled in Cancer Discovery Announcing SARS-CoV-2 T cell antigen discovery program Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Feb. READ MORE >
Feb 04, 2021
Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2020 financial results and corporate update conference call and live audio webcast READ MORE >
Jan 28, 2021
Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform
Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigens of anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T cell responses CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. READ MORE >

Event and Presentations

Genocea presents regularly at top-tier scientific and investor conferences.

Events image
Past Event
Feb 25, 2021 10:00 AM EST
SVB Leerink Global Healthcare Conference
Listen to webcast
Events image
Past Event
Feb 17, 2021 11:30 PM EST
LifeSci Advisors Precision Oncology Day
Listen to webcast

Corporate Governance

The Board of Directors of Genocea Biosciences (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Financials and Filings

Contact Us